key: cord-0867552-or7h7jka
authors: Spinoni, Enrico Guido; Mennuni, Marco; Rognoni, Andrea; Grisafi, Leonardo; Colombo, Crizia; Lio, Veronica; Renda, Giulia; Foglietta, Melissa; Petrilli, Ivan; D’Ardes, Damiano; Sainaghi, Pier Paolo; Aimaretti, Gianluca; Bellan, Mattia; Castello, Luigi; Avanzi, Gian Carlo; Corte, Francesco Della; Krengli, Marco; Pirisi, Mario; Malerba, Mario; Capponi, Andrea; Gallina, Sabina; Pierdomenico, Sante Donato; Cipollone, Francesco; Patti, Giuseppe
title: Contribution of Atrial Fibrillation to In-Hospital Mortality in Patients With COVID-19
date: 2021-02-17
journal: Circ Arrhythm Electrophysiol
DOI: 10.1161/circep.120.009375
sha: d631802c2887c21687b325e99ad32ef85c35e8d5
doc_id: 867552
cord_uid: or7h7jka

nan

A trial fibrillation (AF) shares with coronavirus infective disease-19 (COVID-19) a higher prevalence of older age, cardiovascular risk factors, and comorbidities. [1] [2] [3] Among patients with COVID-19, a history of AF is reported in ≈20% of cases, 4 and new-onset AF represents a common complication, especially in those with a more severe disease. [1] [2] [3] We specifically investigated the prognostic role of AF on in-hospital outcome in consecutive patients admitted for COVID-19 in 3 Italian Institutions (Hospitals of Novara, Vercelli, and Chieti).

We retrospectively included consecutive patients aged ≥18 years hospitalized for COVID-19 from February to May 2020. The study protocol was approved by the institutional ethical committee (Institutional Review Board code CE 97/20), and patients gave informed consent to participate. All patients received a 12-lead ECG on admission. Additional electrocardiograms were performed every 48 hours in patients receiving QT-interval prolonging drugs (>90% of the whole population) or when clinically indicated. Patients were divided according to presence (either historical or new-onset) or absence of AF during the hospitalization for COVID-19. Historical AF was defined as a past medical history of AF.

Primary end point was in-hospital all-cause mortality in patients with versus those without AF and in patients with different AF subtypes (historical and new-onset) versus those without AF. The following end points were also evaluated during in-hospital stay: cardiovascular mortality and severe acute respiratory distress syndrome. Logistic regression models were used to estimate the independent association between AF and study end points, including demographic factors, comorbidities, laboratory findings, and in-hospital treatments.

A total of 637 patients were enrolled; 503 (79%) patients had no AF, and 134 (21%) had in-hospital AF (historical in 79 patients and new-onset in 55). Compared with patients without AF, those with AF were older and presented a higher prevalence of female sex, arterial hypertension, diabetes, cardiomyopathy, peripheral artery disease, chronic kidney disease, and chronic obstructive pulmonary disease. White blood cell count and C-reactive protein were increased and PaO 2 /FiO 2 was reduced in the subset with new-onset versus historical AF.

In-hospital mortality was higher in patients with AF (44.4% versus 22.1% in those without, P=0.001); 30-day estimated survival rates by Kaplan-Meier method were 39.6% (95% CI, 27.8%-50.8%) versus 59.4% (51.4%-66.5%), respectively (log-rank P<0.001; Figure  [A This study indicates that AF, especially new-onset, is an independent predictor of in-hospital all-cause mortality, cardiovascular death, and more severe clinical pattern in patients admitted for COVID-19. Given the risk of residual confounding, such association does not prove causation, as AF can be only a risk marker. Nevertheless, multiple adjustments for potential confounders and the finding that in-hospital AF was associated with lower survival mainly in patients with low or intermediate CHA 2 DS 2-VASc score (ie, with fewer comorbidities) support that AF might, at least in part, directly impact mortality. Furthermore, patients with new-onset AF had a more severe COVID-19 presentation. This supports that new-onset AF is related to the degree of inflammatory and hypoxemic viral insult, and may further enhance the hypercoagulable state, endothelial dysfunction, and oxidative stress of COVID-19 patients, with consequent worsening in prognosis. The authors will make the data, methods used in the analysis, and materials used to conduct the research available to any researcher for purposes of reproducing the results.

atrial fibrillation COVID-19 coronavirus infective disease-19 OR odds ratio

COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options

Italian National Institute of Health COVID-19 Mortality Group. Clinical characteristics of hospitalized individuals dying with COVID-19 by age group in Italy

Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy

COVID-19 and cardiac arrhythmias